Urology Doctors in Williamsburg, VA Accepting Medicare

4 Urology doctors found. Showing 1 - 4

Dr. Edward Bedell Freyfogle Jr., MD Urology Medicare: Not Enrolled in Medicare Practice Location: 104 Hoylake, Williamsburg, VA 23188 Phone: 757-645-2495

Anthony J. Taylor, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 120 Kings Way, Suite 3200, Williamsburg, VA 23185 Phone: 757-251-0051    Fax: 757-466-1310

Scott Vassar Burgess, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 120 Kings Way, Suite 3200, Williamsburg, VA 23185 Phone: 757-253-0051    Fax: 757-229-9526

Lawrence R. Volz, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 400 Sentara Cir Ste 310, Williamsburg, VA 23188 Phone: 757-345-5554    Fax: 757-345-2288

News Archive

Lawyers, doctors team to ensure health safety net for poor

In the District of Columbia, "[a]s part of a medical-legal partnership that began in 2002, lawyers work alongside doctors at four District clinics run by [Children's National Medical Center]. Their shared goal is to overcome legal and social challenges that threaten the care of their patients — low-income children, predominantly African American, and virtually all covered by Medicaid."

Diabetes over-treatment could be more dangerous for elderly find study

Diabetes, especially type 2 diabetes mellitus affects a large population across the globe. Treatment usually comprises of the use of oral drugs that could reduce the blood sugar and keep the glycosylated hemoglobin levels or HbA1c less than 7 percent.

Study examines the influence of unexpected task constraint on voluntary task switching

Kessler Foundation scientists have published results of cognitive research that show the negative effects that unexpected task constraint, following self-generated task choice, has on task-switching performance.

Provectus' PV-10 data for intralesional treatment of solid tumors presented at ASCO annual meeting

Provectus Biopharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that data on its investigational agent PV-10 for intralesional (IL) treatment of solid tumors were featured in two presentations in the Poster Highlights Session, Melanoma/Skin Cancers, on June 2, 2014 during the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL.

OncoGenex Pharmaceuticals to pay Isis Pharmaceuticals $10M for license of OGX-011 to Teva Pharmaceutical Industries

Isis Pharmaceuticals, Inc. today announced that it will receive a $10 million payment from OncoGenex Pharmaceuticals, Inc. as a result of OncoGenex' license of OGX-011 to Teva Pharmaceutical Industries Ltd. ( TEVA). OGX-011 is a second-generation antisense drug co-discovered by Isis and OncoGenex that has completed a successful Phase 2 program in patients with advanced prostate cancer and advanced non-small cell lung cancer.

Read more Medical News

› Verified 5 days ago